{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:15:16Z","timestamp":1787764516269,"version":"build-2784847793"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017003","name":"Peking University Health Science Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>We aimed to explore the efficacy and safety of efgartigimod in patients with refractory immune-mediated necrotizing myopathy (IMNM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This open-label pilot observational study included seven patients with refractory IMNM, all of whom received intravenous efgartigimod treatment. The clinical response was assessed after 4 weeks of efgartigimod treatment according to the 2016 American College of Rheumatology\u2013European League Against Rheumatism response criteria for adult idiopathic inflammatory myopathy. Serum levels of immunoglobulin as well as anti\u2013signal recognition particle (SRP) and anti\u20133-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) antibodies were measured using enzyme-linked immunosorbent assays and commercial line immunoblot assays. Safety assessments included evaluations of adverse events and severe adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The seven patients with refractory IMNM included five cases with anti-HMGCR antibodies and two cases within anti-SRP antibodies. Four of the seven patients achieved clinical responses. The total improvement score for the responders at 4 weeks were 32.5, 40.0, 47.5, and 70.0, and those at 8 weeks were 27.5, 47.5, 57.5, and 70.0. In comparison to the responsive patients, the non-responsive patients had longer durations [8 (-) versus 2 (1\u20135) years, <jats:italic>P<\/jats:italic> = 0.03], and more chronic myopathic features by muscle biopsy (67% versus 0%, <jats:italic>P<\/jats:italic>\u00a0= 0.046). Serum immunoglobulin G levels (11.2 \u00b1 2.5 versus 5.7 \u00b1 2.5, <jats:italic>P<\/jats:italic> = 0.007) and anti-HMGCR\/SRP antibody levels (97.2 \u00b1 6.9 versus 41.8 \u00b1 16.8, <jats:italic>P<\/jats:italic> = 0.002) were decreased after treatment compared with baseline levels. Adverse events were reported in one of the seven patients, who showed mild headache.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Despite its small size, our study demonstrated that promoting the degradation of endogenous immunoglobulin G may be effective for patients with IMNM. Efgartigimod may be a promising option for cases of refractory IMNM to shorten duration and minimize chronic myopathic features.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1447182","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T04:57:46Z","timestamp":1729573066000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Treatment of refractory immune-mediated necrotizing myopathy with efgartigimod"],"prefix":"10.3389","volume":"15","author":[{"given":"MengTing","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JingChu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YiKang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HongJun","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhaoXia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YaWen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscular disorders: NMD"},{"key":"B2","doi-asserted-by":"publisher","first-page":"102993","DOI":"10.1016\/j.autrev.2021.102993","article-title":"Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge","volume":"21","author":"Merlonghi","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2014.01.002","article-title":"Myopathy with anti-signal recognition particle antibodies: clinical and histopathological features in Chinese patients","volume":"24","author":"Wang","year":"2014","journal-title":"Neuromuscular disorders: NMD"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/tan.v101.5","article-title":"Association of immune-mediated necrotizing myopathy with HLA polymorphisms","volume":"101","author":"Ohnuki","year":"2023","journal-title":"Hla"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.670784","article-title":"The clinicopathological distinction between seropositive and seronegative immune-mediated necrotizing myopathy in China","volume":"12","author":"Ma","year":"2021","journal-title":"Front neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213518","article-title":"In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy","volume":"78","author":"Bergua","year":"2019","journal-title":"Ann rheumatic diseases"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.3390\/biomedicines10082036","article-title":"Prevention of anti-HMGCR immune-mediated necrotising myopathy by C5 complement inhibition in a humanised mouse model","volume":"10","author":"Julien","year":"2022","journal-title":"Biomedicines"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead298","article-title":"Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy","volume":"62","author":"Julien","year":"2023","journal-title":"Rheumatol (Oxford England)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1756286421998918","DOI":"10.1177\/1756286421998918","article-title":"Rituximab in the treatment of immune-mediated necrotizing myopathy: a review of case reports and case series","volume":"14","author":"Xiong","year":"2021","journal-title":"Ther Adv neurological Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22920","article-title":"Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle","volume":"69","author":"Pinal-Fernandez","year":"2017","journal-title":"Arthritis Care Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13023-015-0277-y","article-title":"Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients","volume":"10","author":"Suzuki","year":"2015","journal-title":"Orphanet J rare diseases"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1301109","article-title":"Anti-SRP immune-mediated necrotizing myopathy responsive to ofatumumab: a case report","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.777502","article-title":"Belimumab for immune-mediated necrotizing myopathy associated with anti-SRP antibodies: A case report and retrospective review of patients treated with anti-B-cell therapy in a single center and literature","volume":"12","author":"Cui","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21968","article-title":"Therapeutic plasma exchange for the treatment of refractory necrotizing autoimmune myopathy","volume":"37","author":"Kruse","year":"2022","journal-title":"J Clin apheresis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/art.v64.12","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis rheumatism"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew470","article-title":"More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"56","author":"Tiniakou","year":"2017","journal-title":"Rheumatol (Oxford England)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13075-019-2093-6","article-title":"Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients","volume":"22","author":"Meyer","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-8966(03)00091-9","article-title":"Muscle magnetic resonance imaging in patients with congenital muscular dystrophy and Ullrich phenotype","volume":"13","author":"Mercuri","year":"2003","journal-title":"Neuromuscul Disord"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2013.05.001","article-title":"Muscle MRI reveals distinct abnormalities in genetically proven non-dystrophic myotonias","volume":"23","author":"Morrow","year":"2013","journal-title":"Neuromuscular disorders: NMD"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.05.011","article-title":"Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis","volume":"14","author":"Ruiz-Arruza","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and\u00a0polymyositis: An International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann rheumatic Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.866701","article-title":"Screening for anti-HMGCR antibodies in a large single myositis center reveals infrequent exposure to statins and diversiform presentation of the disease","volume":"13","author":"Szczesny","year":"2022","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10621-7","article-title":"Anti-HMGCR myopathy overlaps with dermatomyositis-like rash: a distinct subtype of idiopathic inflammatory myopathy","volume":"269","author":"Hou","year":"2022","journal-title":"J neurol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.3390\/biomedicines12061214","article-title":"Real-world case series of efgartigimod for Japanese generalized myasthenia gravis: well-tailored treatment cycle intervals contribute to sustained symptom control","volume":"12","author":"Konno","year":"2024","journal-title":"Biomedicines"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02856-3","article-title":"Efgartigimod and ravulizumab for treating acetylcholine receptor auto-antibody-positive (AChR-ab+) generalized myasthenia gravis: indirect treatment comparison","volume":"41","author":"van Steen","year":"2024","journal-title":"Adv Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-023-02637-2","article-title":"Senescent fibro-adipogenic progenitors are potential drivers of pathology in inclusion body myositis","volume":"146","author":"Nelke","year":"2023","journal-title":"Acta neuropathologica"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01460-5","article-title":"Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Broome","year":"2023","journal-title":"Lancet (London England)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0298","article-title":"Clinical efficacy and safety of efgartigimod for treatment\u00a0of\u00a0myasthenia gravis","volume":"15","author":"Sivadasan","year":"2023","journal-title":"Immunotherapy"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.v186.3","article-title":"Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br J Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1284444","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2023","journal-title":"Front neurol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1400459","article-title":"Case report: A highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1447182\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T04:57:49Z","timestamp":1729573069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1447182\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2024.1447182"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1447182","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]},"article-number":"1447182"}}